Prospective analysis of prostate-specific markers in pelvic lymph nodes of patients with high-risk prostate cancer

Journal of the National Cancer Institute

Volumn 89, Issue 20, 1997, Pages 1498-1504

  Ferrari, Anna C ^a,c   Stone, Nelson N ^a   Eyler, Jason N ^a   Gao, Min ^a   Mandeli, John ^a   Unger, Pamela ^a   Gallagher, Robert E ^b   Stock, Richard ^a  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^b ALBERT EINSTEIN CANCER CENTER   (United States)

^c MOUNT SINAI MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

ANTIGEN DETECTION; ARTICLE; CLINICAL ARTICLE; HIGH RISK POPULATION; HUMAN; LYMPH NODE METASTASIS; MALE; METASTASIS POTENTIAL; PELVIS LYMPH NODE; PROSTATE BIOPSY; PROSTATE CANCER; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RISK ASSESSMENT;

EID: 0030800663     PISSN: 00278874     EISSN: None     Source Type: Journal    
DOI: 10.1093/jnci/89.20.1498     Document Type: Article

References (48)

1. Smith JA Jr, Middleton RG. Implications of volume of nodal metastasis in patients with adenocarcinoma of the prostate. J Urol 1985;133:17.
2. Prout GR Jr, Heaney JA, Griffin PP, Daly JJ, Shipley WU. Nodal involvement as a prognostic indicator in patients with prostatic carcinoma. J Urol 1980;124:226-31.
3. Kramer SA, Cline WA Jr, Farnham R, Carson CC, Cox EB, Hinshaw W, et al. Prognosis of patients with stage D1 prostatic adenocarcinoma. J Urol 1981;125:817-9.
4. Gervasi LA, Mata J, Easley JD, Wilbanks JH, Seale-Hawkins C, Carlton CE Jr, et al. Prognostic significance of lymph nodal metastases in prostate cancer. J Urol 1989;142:332-6.
5. Narayan P, Gajendran V, Taylor SP, Tewari A, Presti JC Jr, Leidich R, et al. The role of transrectal ultrasound-guided biopsy-based staging, preoperative serum prostate-specific antigen, and biopsy Gleason score in prediction of final pathologic diagnosis in prostate cancer. Urology 1995;46: 205-12.
6. Partin AW, Yoo J, Carter HB, Pearson JD, Chan DW, Epstein JI, et al. The use of prostate specific antigen, clinical stage, and Gleason score to predict pathological stage in men with localized prostate cancer. J Urol 1993;150: 110-4.
7. Danella JF, de Kernion JB, Smith RB, Steckel J. The contemporary incidence of lymph node metastases in prostate cancer: implications for laparoscopic lymph node dissection. J Urol 1993;149:1488-91.
8. Fair WR, Aprikian A, Sogani P, Reuter V, Whitmore WF Jr. The role of neoadjuvant hormonal manipulation in localized prostatic cancer. Cancer 1993;71(3 Suppl):1031-8.
9. D'Amico AV, Whittington R, Malkowicz SB, Schultz D, Schnall M, Tomaszewski JE, et al. A multivariate analysis of clinical and pathological factors that predict for prostate specific antigen failure after radical prostatectomy for prostate cancer. J Urol 1995;154:131-8.
10. Freeman JA, Esrig D, Grossfeld GD, Stein JP, Chen SC, Young LL, et al. Incidence of occult lymph node metastases in pathological stage C (pT3N0) prostate cancer. J Urol 1995;154:474-8.
11. Freeman JA, Hill C, Esrig D, Grossfeld GD, Stein JP, Chen SC, et al. Occult lymph node metastases correlate with recurrence and survival in pathologic stage C (pT3N0) prostate cancer [abstract]. Proc Am Urol Assoc 1996;155:420A.
12. Stone NN, Stock RG, Unger P. Indications for seminal vesicle biopsy and laparoscopic pelvic lymph node dissection in men with localized carcinoma of the prostate. J Urol 1995;154:1392-6.
13. Rioja Sanz C, Blas-Marin M, Rioja Sanz L. Laparoscopic pelvic lymphadenectomy in the staging of prostate cancer. Eur Urol 1993;24 Suppl 2:19-21.
14. Scher H, Isaacs JT, Fuks Z, Walsh PC. Prostate. In: Abeloff MD, Armitage JO, Lichter AS, Niederhuber JE, editors. Clinical oncology. New York: Churchill Livingstone, 1995:1439-72.
15. Bostwick D. Neoplasms of the prostate. In: Bostwick D, Eble J, editors. Urologic surgical pathology. 1st ed. St. Louis (MO): Mosby, 1997: 343-422.
16. Frazier HA, Robertson JE, Humphrey PA, Paulson DF. Is prostate specific antigen of clinical importance in evaluating outcome after radical prostatectomy. J Urol 1993;149:516-8.
17. Denis LJ. Staging and prognosis of prostate cancer. Eur Urol 1993;24: 13-8.
18. Paulson DF, Moul JW, Walther PJ. Radical prostatectomy for clinical stage T1-2N0M0 prostatic adenocarcinoma: long-term results. J Urol 1990;144: 1180-4.
19. Stein A, de Kernion JB, Smith RB, Dorey F, Patel H. Prostate specific antigen levels after radical prostatectomy in patients with organ confined and locally extensive prostate cancer. J Urol 1992;147:942-6.
20. Oesterling JE. Prostate specific antigen: a critical assessment of the most useful tumor marker for adenocarcinoma of the prostate. J Urol 1991;145: 907-23.
21. Israeli RS, Powell CT, Corr JG, Fair WR, Heston WD. Expression of the prostate-specific membrane antigen. Cancer Res 1994;54:1807-11.
22. Wright GL, Haley C, Beckett ML, Schellhammer PF. Expression of prostate-specific membrane antigen in normal, benign, and malignant prostate tissues. Urol Oncol 1995;1:18-28.
23. Wolf DA, Schulz P, Fittler F. Transcriptional regulation of prostate kallikrein-like genes by androgen. Mol Endocrinol 1992;6:753-62.
24. Papsidero LD, Kuriyama M, Wang MC, Horoszewicz J, Leong SS, Valenzuela L, et al. Prostate antigen: a marker for human prostate epithelial cells. J Natl Cancer Inst 1981;66:37-42.
25. Partin AW, Getzenberg RH, CarMichael MJ, Vindivich D, Yoo J, Epstein JI, et al. Nuclear matrix protein patterns in human benign prostatic hyperplasia and prostate cancer. Cancer Res 1993;53:744-6.
26. Stege R, Tribukait B, Lundh B, Carlstrom K, Pousette A, Hasenson M. Quantitative estimation of tissue prostate specific antigen, deoxyribonucleic acid ploidy and cytological grade in fine needle aspiration biopsies for prognosis of hormonally treated prostatic carcinoma. J Urol 1992;148: 833-7.
27. Keillor JS, Aterman K. The response of poorly differentiated prostatic tumors to staining for prostate specific antigen and prostatic acid phosphatase: a comparative study. J Urol 1987;137:894-6.
28. Ford TF, Butcher DN, Masters JR, Parkinson MC. Immunocytochemical localisation of prostate-specific antigen: specificity and application to clinical practice. Br J Urol 1985;57:50-5.
29. Israeli RS, Powell CT, Fair WR, Heston WD. Molecular cloning of a complementary DNA encoding a prostate-specific membrane antigen. Cancer Res 1993;53:227-30.
30. Katz AE, Olsson CA, Raffo AJ, Cama C, Perlman H, Seaman E, et al. Molecular staging of prostate cancer with the use of an enhanced reverse transcriptase-PCR assay. Urology 1994;43:765-75.
31. Katz AE, de Vries GM, Begg MD, Raffo AJ, Cama C, O'Toole C, et al. Enhanced reverse transcriptase-polymerase chain reaction for prostate specific antigen as an indicator of true pathologic stage in patients with prostate cancer. Cancer 1995;75:1642-8.
32. Cama C, Olsson CA, Raffo AJ, Perlman H, Buttyan R, O'Toole K, et al. Molecular staging of prostate cancer. II. A comparison of the application of an enhanced reverse transcriptase polymerase chain reaction assay for prostate specific antigen versus prostate specific membrane antigen. J Urol 1995;153:1373-8.
33. de Vries GM, Olsson CA, Benson MC, Connor JP, Buttyan R, Katz AE. Qualitative and quantitative RT-PCR for PSA molecular staging of prostate cancer [abstract]. Proc Am Urol Assoc 1996;155:417A.
34. Su SL, Cookson MS, Miller WH, Ball TP, Sarosdy MF. Molecular staging of clinically localized prostate cancer: lack of predictive value [abstract]. Proc Am Urol Assoc 1996;155:322A.
35. Ignatoff JM, Oefelein MG, Herz B, Watkin W, Kaul KL. Prostate specific antigen (PSA) reverse transcriptase-polymerase chain reaction (RT-PCR) assay in preoperative staging of prostate cancer [abstract]. Proc Am Urol Assoc 1996;155:417A.
36. Sokoloff MH, Tso CL, Kaboo R, Nelson S, Ko J, Dorey F, et al. Quantitative polymerase chain reaction does not improve preoperative prostate cancer staging: a clinicopathological molecular analysis of 121 patients. J Urol 1996;156:1560-6.
37. Oefelein MG, Herz B, Ignatoff JM, Kaul KL. Longitudinal assessment by prostate specific antigen (PSA) reverse transcriptase-polymerase chain reaction (RT-PCR) of circulating prostate epithelial cells following radical retropubic prostatectomy (RRP) [abstract]. Proc Am Urol Assoc 1996;155: 552A.
38. Israeli RS, Miller WH Jr, Su SL, Powell CT, Fair WR, Samadi DS, et al. Sensitive nested reverse transcription polymerase chain reaction detection of circulating prostatic tumor cells: comparison of prostate-specific membrane antigen and prostate-specific antigen-based assays. Cancer Res 1994; 54:6306-10.
39. Eschwege P, Dumas F, Blanchet P, Le Maire V, Benoit G, Jardin A, et al. Haematogenous dissemination of prostatic epithelial cells during radical prostatectomy. Lancet 1995;346:1528-30.
40. Ferrari AC, Tao W, Baldwin Y, Ossowski L, Waxman S, Stone N. Detection of circulating metastatic tumor cells by PSA and PSM may be useful to identify subgroups of advanced prostate cancer patients [abstract]. Proc Am Assoc Cancer Res 1996;37:247.
41. Melchior SW, Corey E, Ellis WJ, Ross AA, Layton TJ, Oswin MM, et al. Early tumor cell dissemination in patients with clinically localized carcinoma of the prostate. Clin Cancer Res 1997;3:249-56.
42. Wood DP, Weinstein M, Humphries S, Rangnekar VM. Prognostic significance of circulating prostate cells [abstract]. Proc Am Urol Assoc 1996; 155:418A.
43. Deguchi T, Doi T, Ehara H, Ito S, Takahashi Y, Nishino Y, et al. Detection of micrometastatic prostate cancer cells in lymph nodes by reverse transcriptase-polymerase chain reaction. Cancer Res 1993;53:5350-4.
44. Takahashi T, Hoshi S, Orikasa S, Kaneda T, Mao H, Suzuki K, et al. Genetic diagnosis of pelvic lymph node metastasis in prostate cancer [abstract]. Proc Am Urol Assoc 1996;155:378A.
45. Edelstein RA, Zietman AL, de las Morenas A, Krane RJ, Babayan RK, Traish A, et al. Implications of prostatic micrometastases to the pelvic lymph nodes: first report of an archival tissue gene expression study [abstract]. Proc Am Urol Assoc 1996;155:550A.
46. Edelstein RA, Krane RJ, Babayan RK, de las Morenas A, Moreland RB. A rapid and simple method for the detection of prostate-specific antigen mRNA in archival tissue specimens using a reverse transcription-polymerase chain reaction assay. Urology 1995;45:597-603.
47. Gallagher RE, Li YP, Rao S, Paietta E, Andersen J, Etkind P, et al. Characterization of acute promyelocytic leukemia cases with PML-RAR α break/fusion sites in PML exon 6: identification of a subgroup with decreased in vitro responsiveness to all-trans retinoic acid. Blood 1995;86: 1540-7.
48. Rosner B. Hypothesis testing: categorical data. In: Kagushev A, editor. Fundamentals of biostatistics. 4th ed. New York: Duxbury Press, 1995: 379-83.